Inspire Medical Systems Inc.
INSP evidence brief
What we can confirm
- BioSniper Score:
- 5.4 / 10
- Market Cap:
- $1.74B
- Lead Asset:
- inspire system (Approved)
What it means
What to watch
Prepared research question
What matters most for INSP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INSP
Inspire Medical Systems Inc. is a medical device company focused on the development and commercialization of its Inspire system for obstructive sleep apnea, with a pipeline extending into Down syndrome and cognition.
Key risk: Regulatory and quality compliance risks
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$1.74B
Cash Runway
—
Lead Asset
inspire system (Approved)
Next Catalyst
—
Tracking 1 pipeline candidate · 9 clinical trials for Inspire Medical Systems Inc..
Inspire Medical Systems Inc. is a medical device company focused on the development and commercialization of its Inspire system for obstructive sleep apnea, with a pipeline extending into Down syndrome and cognition.
- As of 2026-06-30, Inspire reported cash & equivalents of $127.8M, total revenue of $200.6M, net income of $0.3M, and shareholders' equity of $781.2M [sec].
- The company's revenue grew from $624.8M in 2023 to $802.8M in 2024, with gross margin improving to 84.7% and net income of $53.5M in 2024 [sec_mda · as of 2025-02-10].
- Inspire's accumulated deficit was $291.9M as of December 31, 2024 [sec_mda · as of 2025-02-10].
- The company is conducting a Phase 3 trial to evaluate hypoglossal nerve stimulation on cognition and language in Down syndrome and obstructive sleep apnea, with topline results expected by 2027-09-30 [upcoming catalysts].
- Inspire's compensation program for fiscal 2025 weighted 65% on financial metrics (with revenue growth as the highest priority) and 35% on strategic metrics [sec · filed 2026-03-20].
What works
- Inspire achieved profitability in 2024 with net income of $53.5M, a significant turnaround from a net loss of $21.2M in 2023 [sec_mda · as of 2025-02-10].
- Revenue growth has been strong, increasing from $407.9M in 2022 to $802.8M in 2024, reflecting expanding market adoption of the Inspire system [sec_mda · as of 2025-02-10].
- The company maintains a high gross margin of 84.7% as of 2024, indicating strong pricing power and cost management [sec_mda · as of 2025-02-10].
- Inspire is investing in next-generation products (Inspire system and SleepSync cloud-based management) and a Phase 3 trial in Down syndrome, which could open new markets [sec_mda · as of 2026-02-13] [upcoming catalysts].
What to weigh
- Inspire has an accumulated deficit of $291.9M as of December 31, 2024, reflecting years of prior losses [sec_mda · as of 2025-02-10].
- The company relies on cash from operations and equity/debt offerings to fund R&D and operations; there is no assurance that future financing will be available on favorable terms [sec_mda · as of 2025-11-03].
- The business is subject to regulatory risks, including FDA inspections, product complaints, and recalls, as overseen by the board's quality committee [sec · filed 2026-03-20].
- Inspire's forward-looking statements caution that actual results may differ materially due to risk factors, including macroeconomic impacts and competitive pressures [sec_mda · as of 2026-08-03].
From the filings
Quoted directly from source documents.
Inspire achieved net income of $53.5M in 2024, a turnaround from prior losses.
“For the year ended December 31, 2024, we generated revenue of $802.8 million with a gross margin of 84.7% and net income of $53.5 million, compared to revenue of $624.8 million with a gross margin of 84.5% and a net loss of $21.2 million for the year ended December 31, 2023”
SEC MD&A · February 10, 2025
Inspire's accumulated deficit was $291.9M as of December 31, 2024.
“Our accumulated deficit as of December 31, 2024 was $291.9 million.”
SEC MD&A · February 10, 2025
Inspire's compensation plan for fiscal 2025 emphasizes revenue growth as the highest priority.
“the Organization and Compensation Committee emphasized revenue growth as the highest priority, given the Company's stage of development and market opportunity.”
SEC filings · March 20, 2026
Catalyst timeline
- 2027-09-30 · Phase3_Topline — Phase 3 Topline: Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive — Topline results from a Phase 3 trial evaluating the Inspire system's effect on cognition and language in Down syndrome patients with obstructive sleep apnea.
Risks & what to watch (4)›
Key risks
- Regulatory and quality compliance risks — Board oversees quality, safety, supply, FDA inspections, and recalls; non-compliance could disrupt operations [sec · filed 2026-03-20].
- Dependence on financing for growth — Company may need additional equity/debt financing; no assurance of favorable terms [sec_mda · as of 2025-11-03].
- Accumulated deficit and past losses — Accumulated deficit of $291.9M as of Dec 31, 2024, despite recent profitability [sec_mda · as of 2025-02-10].
- Forward-looking uncertainties — Actual results may differ materially due to risk factors including macroeconomic conditions [sec_mda · as of 2026-08-03].
What to watch
- Phase 3 topline results for hypoglossal nerve stimulation in Down syndrome and obstructive sleep apnea, expected by 2027-09-30 [upcoming catalysts].
- Revenue growth trajectory and ability to sustain profitability, given the emphasis on revenue as a key metric [sec · filed 2026-03-20].
- Progress in next-generation product development (Inspire system and SleepSync) and associated R&D spending [sec_mda · as of 2026-02-13].
- Cash runway and any future financing activities, as the company relies on operations and capital markets [sec_mda · as of 2025-11-03].
Sources: SEC filings · SEC MD&A · Generated August 7, 2026 · How we verify sources →
Run Inspire Medical Systems Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Inspire Medical Systems Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
1 candidate
No upcoming catalysts tracked
0 buys · 3 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 11, 2026- % of float
- 13.1%
- Days to cover
- 2.8
- Shares short
- 2,888,404
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INSP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Inspire Medical Systems Inc.?
Inspire Medical Systems Inc. is a medical device company focused on the development and commercialization of its Inspire system for obstructive sleep apnea, with a pipeline extending into Down syndrome and cognition.
What is Inspire Medical Systems Inc.'s lead drug candidate?
Inspire Medical Systems Inc.'s most advanced tracked candidate is inspire system (Approved) for Moderate to severe obstructive sleep apnea (OSA).
Who is the CEO of Inspire Medical Systems Inc.?
Mr. Timothy P. Herbert is the chief executive officer of Inspire Medical Systems Inc. (INSP).
Where is Inspire Medical Systems Inc. headquartered?
Inspire Medical Systems Inc. (INSP) is headquartered in Golden Valley, MN, United States.
What therapeutic areas does Inspire Medical Systems Inc. focus on?
Inspire Medical Systems Inc. develops therapies across Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.